Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Planning and Dissemination Grant - Institute Community Support

University of Calgary

$15,000.00

Cardiovascular Health in Transgender Hormone-Therapy Research Priority Setting

EF 2022-23

Résumé
Transgender individuals (gender identity does not align with sex at birth) face significant health inequities and disparities. The prevalence of gender-affirming hormone therapy use to gain characteristics ascribed to their desired gender identity is increasing, yet current hormone therapy guidelines are inadequately designed using cisgender (gender identity aligns with sex at birth) data, research, and reference ranges. Currently, health researchers, clinicians and gender medicine specialists lack the directive of patient-identified priorities for ensuring safe and accessible gender-affirming hormone therapy use. Project Goals: (i) Disseminate existing evidence on the effects of gender-affirming hormone therapy on cardiovascular health to key stakeholders; (ii) Identify the top 10 cardiovascular research priorities for transgender and gender-diverse individuals with lived experience, their caregivers, and the clinicians and policy-makers involved in their care to guide researchers and inform funders; (iii) Build capacity for shared initiatives and future research agendas to optimize transgender and gender-diverse health in Canada. To inform and carry out these objectives in a meaningful fashion, we will host a 1-day event in Calgary, AB to discuss the state of the science of cardiovascular health in transgender adults, and create consensus on patient-identified priorities for gender-affirming hormone therapy use for transgender cardiovascular health. Our expert-focused team, complete with individuals with lived experience and their caregivers, clinicians, researchers, decision-makers, funders and opinion leaders will ensure that our inclusive and patient-oriented event will catalyze the incorporation of these essential topics into mainstream research on a global level.
Programme
Planning and Dissemination Grant - Institute Community Support
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
480849
Name
Rytz Chantal
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Planning and Dissemination Grants
Projecttitle
Cardiovascular Health in Transgender Hormone-Therapy Research Priority Setting
Programtype2
Miscellaneous Programs
Orgnameinp2
University of Calgary
Cihramount2
$15,000
Cihrequipment2
$0
Programname2
Planning and Dissemination Grant - Institute Community Support
Keyworddelim
Cardiovascular Health; Community Engagement; Estrogen; Gender-Affirming Hormone Therapy; Gender-Diverse; Non-Binary; Patient-Identified Priorities; Priority Setting; Testosterone; Transgender Health
Abstract
Transgender individuals (gender identity does not align with sex at birth) face significant health inequities and disparities. The prevalence of gender-affirming hormone therapy use to gain characteristics ascribed to their desired gender identity is increasing, yet current hormone therapy guidelines are inadequately designed using cisgender (gender identity aligns with sex at birth) data, research, and reference ranges. Currently, health researchers, clinicians and gender medicine specialists lack the directive of patient-identified priorities for ensuring safe and accessible gender-affirming hormone therapy use. Project Goals: (i) Disseminate existing evidence on the effects of gender-affirming hormone therapy on cardiovascular health to key stakeholders; (ii) Identify the top 10 cardiovascular research priorities for transgender and gender-diverse individuals with lived experience, their caregivers, and the clinicians and policy-makers involved in their care to guide researchers and inform funders; (iii) Build capacity for shared initiatives and future research agendas to optimize transgender and gender-diverse health in Canada. To inform and carry out these objectives in a meaningful fashion, we will host a 1-day event in Calgary, AB to discuss the state of the science of cardiovascular health in transgender adults, and create consensus on patient-identified priorities for gender-affirming hormone therapy use for transgender cardiovascular health. Our expert-focused team, complete with individuals with lived experience and their caregivers, clinicians, researchers, decision-makers, funders and opinion leaders will ensure that our inclusive and patient-oriented event will catalyze the incorporation of these essential topics into mainstream research on a global level.
Competitiondate
202302
Approvedterm2
1 yr 0 mth
Pinamesdelim
Rytz, Chantal
Approvedterm
1 an 0 mois
Cihrcontribution2
ICRH~ $15,000~ $0~